Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Carisma Therapeutics Inc's Business Segments
Carisma Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Reporting Segment
Total Revenue
$ 45
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Reporting Segment100%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reporting Segment | $ 45 | 100% |
Annual Results
Revenue Share by Reportable Segment - FY
- Reporting Segment100%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reporting Segment | $ 45 | 100% |
Description of Carisma Therapeutics Inc
Carisma Therapeutics Inc is a biotechnology company that specializes in the development of novel chimeric antigen receptor (CAR)-macrophage therapy to treat cancer. The company was founded in 2019 and is headquartered in Philadelphia, Pennsylvania.
The main focus of Carisma Therapeutics is to harness the power of the immune system to eliminate cancer cells. They are leading the development of a new class of CAR-macrophage therapies that combine the advantages of CAR-T cell therapies with the unique capabilities of macrophages.
CAR-macrophage therapy is a form of immunotherapy that involves genetically engineering macrophages, which are innate immune cells, to express chimeric antigen receptors. These receptors enable macrophages to recognize and destroy cancer cells in a highly specific manner.
Carisma Therapeutics has developed a proprietary platform called CAR-Mφ, which allows for the efficient modification of macrophages with chimeric antigen receptors. This platform enables the company to target a wide range of cancer-specific antigens and enhance the anti-tumor activity of macrophages.
One of the major advantages of CAR-macrophage therapy is that macrophages have the ability to infiltrate solid tumors more effectively than T cells, which are typically used in CAR-T cell therapies. This increased tumor penetration of macrophages can result in a more comprehensive tumor eradication.
Carisma Therapeutics is currently utilizing its CAR-Mφ platform to develop therapies for several types of cancer, including solid tumors and hematological malignancies. They have also collaborated with leading academic institutions and research organizations to expand their understanding of CAR-macrophage therapy and identify new therapeutic targets.
In addition to its innovative CAR-Mφ platform, Carisma Therapeutics has a world-class team of scientists, clinicians, and industry experts who are dedicated to advancing the field of cancer immunotherapy. They are focused on translating their discoveries into clinical applications that can make a significant impact on patient outcomes.
The company has secured significant funding to support its research and development efforts. Carisma Therapeutics has raised over $87 million in Series A financing, which has allowed them to accelerate their preclinical and clinical development programs.
In summary, Carisma Therapeutics Inc is a pioneering biotechnology company that is revolutionizing cancer treatment through the development of CAR-macrophage therapy. Their innovative CAR-Mφ platform and collaborative approach position them as a leader in the field of immunotherapy, with the potential to transform the way cancer is treated.
The main focus of Carisma Therapeutics is to harness the power of the immune system to eliminate cancer cells. They are leading the development of a new class of CAR-macrophage therapies that combine the advantages of CAR-T cell therapies with the unique capabilities of macrophages.
CAR-macrophage therapy is a form of immunotherapy that involves genetically engineering macrophages, which are innate immune cells, to express chimeric antigen receptors. These receptors enable macrophages to recognize and destroy cancer cells in a highly specific manner.
Carisma Therapeutics has developed a proprietary platform called CAR-Mφ, which allows for the efficient modification of macrophages with chimeric antigen receptors. This platform enables the company to target a wide range of cancer-specific antigens and enhance the anti-tumor activity of macrophages.
One of the major advantages of CAR-macrophage therapy is that macrophages have the ability to infiltrate solid tumors more effectively than T cells, which are typically used in CAR-T cell therapies. This increased tumor penetration of macrophages can result in a more comprehensive tumor eradication.
Carisma Therapeutics is currently utilizing its CAR-Mφ platform to develop therapies for several types of cancer, including solid tumors and hematological malignancies. They have also collaborated with leading academic institutions and research organizations to expand their understanding of CAR-macrophage therapy and identify new therapeutic targets.
In addition to its innovative CAR-Mφ platform, Carisma Therapeutics has a world-class team of scientists, clinicians, and industry experts who are dedicated to advancing the field of cancer immunotherapy. They are focused on translating their discoveries into clinical applications that can make a significant impact on patient outcomes.
The company has secured significant funding to support its research and development efforts. Carisma Therapeutics has raised over $87 million in Series A financing, which has allowed them to accelerate their preclinical and clinical development programs.
In summary, Carisma Therapeutics Inc is a pioneering biotechnology company that is revolutionizing cancer treatment through the development of CAR-macrophage therapy. Their innovative CAR-Mφ platform and collaborative approach position them as a leader in the field of immunotherapy, with the potential to transform the way cancer is treated.
Carisma Therapeutics Inc. is a biotechnology company focused on innovating in the field of immunotherapy through the development of unique products and services. Their primary aim is to harness the power of the immune system, particularly using engineered macrophages, to create therapeutic options for various diseases such as cancer.
Segments
1. Oncology Segment:
Carisma Therapeutics is primarily targeting oncology, where it is developing therapies aimed at treating solid tumors. The companys approach revolves around leveraging macrophages, a type of immune cell known for their ability to engulf and destroy pathogens, to specifically target and eliminate cancer cells.
2. Cell Therapy Segment:
The company specializes in cell therapy, where they modify patients immune cells to improve their ability to fight cancer. This segment is characterized by the development of novel cell products that can be administered to patients as part of their treatment regimen.
3. Research and Development Segment:
Carisma places a strong emphasis on R&D, focusing on the advancement of their proprietary technology platforms. This includes preclinical and clinical studies, aimed at exploring new therapeutic avenues and validating the efficacy and safety of their products.
Products
1. CAR-Macrophage Therapeutics:
The cornerstone of Carismas product line is their CAR (Chimeric Antigen Receptor) macrophage therapies. These include products designed to be genetically engineered macrophages that express CARs, allowing them to specifically target antigens present on cancer cells. This innovation aims to improve the immune response against tumors compared to traditional therapies.
2. Preclinical Product Pipeline:
Carisma is actively developing several preclinical candidates based on its CAR-M platform. Each candidate targets specific tumor-associated antigens, with the goal of providing tailored therapies that enhance effectiveness while minimizing side effects associated with conventional cancer treatments.
3. Combination Therapies:
The company is exploring combination therapies that integrate CAR macrophages with existing treatment modalities, such as checkpoint inhibitors or other immunotherapies. This strategic approach aims to enhance overall therapeutic efficacy and patient outcomes.
Services
1. Collaborative Research Partnerships:
Carisma engages in partnerships with academic institutions and other biopharmaceutical companies for collaborative research. These partnerships often involve joint efforts in R&D to explore new therapeutic approaches and share scientific knowledge.
2. Clinical Trial Management:
An essential aspect of Carisma’s operations involves managing clinical trials to evaluate the safety and efficacy of its products. This includes designing and executing clinical studies, recruiting participants, and monitoring outcomes.
3. Regulatory Affairs Consulting:
Carisma provides expertise in navigating the regulatory landscape associated with bringing new biological therapies to market. This includes preparing documentation for regulatory submissions and ensuring compliance with health authorities.
4. Educational Outreach:
The company participates in educating healthcare professionals about their innovative therapies. This may involve organizing seminars, workshops, and conferences focused on the science behind their products and the potential impact on patient care.
Conclusion
Carisma Therapeutics Inc. stands at the forefront of immunotherapy research, particularly within oncology through its groundbreaking CAR-M technology. By leveraging their unique product offerings and engaging in strategic collaborations, the company aims to significantly alter the treatment landscape for patients with cancer, presenting promising alternatives to traditional therapies.
Segments
1. Oncology Segment:
Carisma Therapeutics is primarily targeting oncology, where it is developing therapies aimed at treating solid tumors. The companys approach revolves around leveraging macrophages, a type of immune cell known for their ability to engulf and destroy pathogens, to specifically target and eliminate cancer cells.
2. Cell Therapy Segment:
The company specializes in cell therapy, where they modify patients immune cells to improve their ability to fight cancer. This segment is characterized by the development of novel cell products that can be administered to patients as part of their treatment regimen.
3. Research and Development Segment:
Carisma places a strong emphasis on R&D, focusing on the advancement of their proprietary technology platforms. This includes preclinical and clinical studies, aimed at exploring new therapeutic avenues and validating the efficacy and safety of their products.
Products
1. CAR-Macrophage Therapeutics:
The cornerstone of Carismas product line is their CAR (Chimeric Antigen Receptor) macrophage therapies. These include products designed to be genetically engineered macrophages that express CARs, allowing them to specifically target antigens present on cancer cells. This innovation aims to improve the immune response against tumors compared to traditional therapies.
2. Preclinical Product Pipeline:
Carisma is actively developing several preclinical candidates based on its CAR-M platform. Each candidate targets specific tumor-associated antigens, with the goal of providing tailored therapies that enhance effectiveness while minimizing side effects associated with conventional cancer treatments.
3. Combination Therapies:
The company is exploring combination therapies that integrate CAR macrophages with existing treatment modalities, such as checkpoint inhibitors or other immunotherapies. This strategic approach aims to enhance overall therapeutic efficacy and patient outcomes.
Services
1. Collaborative Research Partnerships:
Carisma engages in partnerships with academic institutions and other biopharmaceutical companies for collaborative research. These partnerships often involve joint efforts in R&D to explore new therapeutic approaches and share scientific knowledge.
2. Clinical Trial Management:
An essential aspect of Carisma’s operations involves managing clinical trials to evaluate the safety and efficacy of its products. This includes designing and executing clinical studies, recruiting participants, and monitoring outcomes.
3. Regulatory Affairs Consulting:
Carisma provides expertise in navigating the regulatory landscape associated with bringing new biological therapies to market. This includes preparing documentation for regulatory submissions and ensuring compliance with health authorities.
4. Educational Outreach:
The company participates in educating healthcare professionals about their innovative therapies. This may involve organizing seminars, workshops, and conferences focused on the science behind their products and the potential impact on patient care.
Conclusion
Carisma Therapeutics Inc. stands at the forefront of immunotherapy research, particularly within oncology through its groundbreaking CAR-M technology. By leveraging their unique product offerings and engaging in strategic collaborations, the company aims to significantly alter the treatment landscape for patients with cancer, presenting promising alternatives to traditional therapies.